Variable Compliance and Persistence with Prescribed Drug Dosing Regimens: Implications for Benefits, Risks, and Economics of Pharmacotherapy

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 767-789

  Urquhart, John ^a,b,c,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AARDEX Group   (Switzerland)

^d NONE   (United States)

Author keywords

"acceptance" and "discontinuation"; Defining optimal dosing regimens; Drug dosing regimens compliance and persistence; Getting recommended dose right; Pharmionics; Prescribed drug dosing regimens; Quality of prescribing; White coat compliance on therapeutic drug monitoring

Indexed keywords

EID: 84889333802     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch46     Document Type: Chapter

References (114)

1. Urquhart J. The electronic medication event monitor-lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345-56.
2. Norell SE. Methods in assessing drug compliance. Acta Med Scand 1984; (suppl 683): 35-40.
3. Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? Pharm J 1990; 245: 213-15.
4. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49: 321-7.
5. Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Ann Rev Pharmacol Toxicol 1997; 37: 451-75.
6. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163-8.
7. Feely M, Cooke J, Price D, Singleton S, Mehta A, Bradford L et al. Low-dose phenobarbitone as an indicator of compliance with drug therapy. Br J Clin Pharmacol 1987; 24: 77-83.
8. Pullar T, Kumar S, Chrystyn H, Rice P, Peaker S, Feely M. The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. Br J Clin Pharmacol 1991; 32: 329-33.
9. Benet LZ, Øie S, Schwartz J. Design and optimization of dosage regimens; harmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, 1996; pp. 1707-92.
10. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377-8.
11. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986; 101: 524-30.
12. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Int Med 1990; 150: 1509-10.
13. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7.
14. Kruse W, Weber E. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561-5.
15. Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990; 4: 199-204.
16. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaij S et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 968-77.
17. Arnsten J, Demas P, Farzadegan H, Grant R, Gourevitch M, Chang C et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33: 1417-23.
18. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS 2002; 16: 599-608.
19. Vrijens B. Analyzing time-varying patterns of human exposure to xenobiotics and their biomedical impact, PhD thesis, University of Gent, Belgium, 2002.
20. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time-course of drug concentration in plasma during a one-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005; 45: 461-7.
21. Vrijens B, Tousset E, Rode R, Bertz R, Mayer SL. Withinpatient variance reduced in an ARV PK study by switching from patient-reported to electronically-compiled dosing times. In: Proceedings of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003.
22. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrobial Chemotherapy 2005; 55: 616-27.
23. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1993; 68 (suppl 3): 49-59.
24. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998; 33: 207-19.
25. Urquhart J. Defining the margins for errors in patient compliance with prescribed drug regimens. Pharmacoeepidemiol Drug Saf 2000; 9: 565-8.
26. Urquhart J. Controlled drug delivery: pharmacologic and therapeutic aspects. J Intern Med 2000; 248: 357-76.
27. World Health Organization. Adherence to Long-term Therapies. Geneva: World Health Organization, 2004.
28. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293-5.
29. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. Can Med Assoc J 1999; 160: 31-7.
30. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3: 417-26.
31. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
32. Urquhart J. Some economic consequences of noncompliance. Curr Hypertens Rep 2001; 3: 473-80.
33. Vrijens B, Tousset E, Koncz T, Métry JM, Urquhart J. Differential economic impact of variable compliance and variable persistence with prescribed, long-term drug regimens. Abstract. Value Health 2003; 6: 200-1.
34. Arlington S, Barnett S, Hughes S, Palo J. Pharma 2010: The Threshold of Innovation. London: IBM Pharmaceutical Consulting Services, 2003.
35. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: noncompliance, nonabsorption, nonresponse. Br J Clin Pharmacol 2002; 54: 212-20.
36. Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002; 11: 439-46.
37. Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug dose after market introduction. Pharmacoepidemiol Drug Saf 2002; 11: 447-53.
38. Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Inf J 1988; 22: 363-78.
39. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990; 263: 1653-7.
40. Urquhart J. History-informed perspectives on the modeling and simulation of therapeutic drug actions. In: Kimko HC, Duffull S, eds, Simulation for Designing Clinical Trials. New York: Marcel Dekker, 2002; pp. 245-69.
41. Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, Lue J et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986; 101: 298-304.
42. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77-87.
43. Is GSK guilty of fraud? Editorial. Lancet 2004; 363: 1919.
44. Cromer B. Behavioral strategies to increase compliance in adolescents. In: Cramer JA, Spilker B, eds, Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991; pp. 99-106.
45. March J. Treatment for adolescents with depression study, in process. New York Times, science section, June 2, 2004.
46. Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther 1994; 1: 260-7.
47. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, eds, Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991; pp. 195-207.
48. Guillebaud J. Any questions. Br Med J 1993; 307: 617.
49. Anonymous. Ten great public health achievements-US, 1900-99: Family planning. Morb Mortal Wkly Rep 1999; 48: 1073-80.
50. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996; 28: 154-8.
51. Wong E, Moeng S, Johnson A. Do Self-Reports of Oral Contraceptive Compliance Agree with Electronic Reports? Tables and statistical report. Report of the Biostatistics and Information Technology Office, Family Health International, Research Triangle Park, NC, October 1995.
52. Peck CC, Urquhart J. Importance of inclusion of information concerning non-compliance with the label-recommended drug regimen. FDA Docket No. 00N-1269, RIN 0910-AA94. Comments on Proposed Rule "Requirements on Content and Format of Labeling for Human Prescription Drugs and Biologics; Requirements for Prescription Drug Product Labels," 2001.
53. Vaur L, Dutrey-Dupagne C, Boussac J, Genes N, Bouvier d'Yvoire M, Elkik F, Meredith PA. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995; 26: 127-31.
54. Hernandez-Hernandez R, Armas de Hernandez MJ, Armas-Padilla MC, Carvajal AR, Guerrero-Pajuelo J. The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Press Monit 1996; 1: 1121-6.
55. Girvin BG, Johnston GD. Comparison of the effects of a 7-day period of noncompliance on blood pressure control using three different antihypertensive agents. J Hypertens 2004; 22: 1409-14.
56. Leenen FHH, Fourney A, Notman G, Tanner J. Persistence of anti-hypertensive effect after "missed doses" of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41: 83-8.
57. Meijer WEE, Bouvy ML, Heerdink ER, Urquhart J, Leufkens HGM. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 179: 519-22.
58. Wood HF, Feinstein AR, Taranta A, Epstein JA, Simpson R. Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae. III. Comparative effectiveness of three prophylaxis regimens in preventing streptococcal infections and rheumatic recurrences. Ann Int Med 1964; 60 (suppl 5): 31-46.
59. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 (suppl 1): 9-195.
60. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, Gomez E, Foresman BH. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-84.
61. What is DOTs? Available at: http://www.who.int/gtb/publications/whatisdots. Accessed: August 18, 2004.
62. Burnier M, Schneider MP, Chiolero A, Fallab Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19: 335-41.
63. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9.
64. Delmas PD, Vrijens B, van de Langerijt L, Roux C, Eastell R, Ringe JD et al. Effect of reinforcement with bone turnover marker results on persistence with risedronate treatment in postmenopausal women with osteoporosis: improving the measurements of persistence on actonel treatment: the Impact study. Presented at the European Calcified Tissues Society Meeting, Rome, May 8-12, 2003.
65. Eastell R, Garnero P, Vrijens B, van de Langerijt L, Pols HAP, Ringe JD et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the Impact study. Presented at the European Calcified Tissues Society Meeting, Rome, May 8-12, 2003.
66. Vrijens B, Ringe JD, Watts NB, Pols HAP, Roux C, Eastell R et al. Electronic monitoring of adherence to therapy in postmenopausal osteoporosis: the Impact study. Presented at the European Calcified Tissues Society Meeting, Rome, May 8-12, 2003.
67. The Lipid Research Clinics Coronary Primary Prevention Trial results: (I) Reduction in incidence of coronary heart disease; (II) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351-74.
68. Manninen V, Elo MO, Frick H, Haapa K, Feinonen OP, Heinsalmi P et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51.
69. Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, Roberts BE, Feely MP. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989; 62: 729-32.
70. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. Compliance with short-term high-dose oestradiol in young patients with primary infertility-new insights from the use of electronic devices. Agents Actions 1990; (suppl 29): 105-15.
71. Granstrom P-A. Progression of visual field defects in glaucoma: relation to compliance with pilocarpine therapy. Arch Ophthalmol 1985; 103: 529-31.
72. Priddy JT, Kass MA, Gordon MO, Meltzer DW, Morley RE. Factors related to compliance with topical pilocarpine treatment. Invest Ophthalmol Vis Sci 1987; 28: 377.
73. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20 (suppl 3): 63-9.
74. Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D, Schweizer R. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21: 833-4.
75. De Geest S, Abraham I, Moons P, Vandeputte M, Van Cleemput J, Evers G, Daenen W, Vanhaecke J. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998; 17: 854-63.
76. Nevins E, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001; 60: 1565-70.
77. Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990; 8: 356-64.
78. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Non-compliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051-7.
79. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880-4.
80. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996; 276: 1955-6.
81. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med 2000; 133: 21-30.
82. Gross R, Bilker QB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15: 2109-17.
83. Arnsten R, Demas J, Farzadegan P, Grant H, Gourevitch R, Chang M et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33: 1417-23.
84. Stone AA, Shiffman S, Schwartz JF, Broderick JF, Hufford MR. Patient noncompliance with paper diaries. BMJ 2002; 324: 1193-4.
85. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental disease. J Nerv Ment Dis 1999; 187: 53-4.
86. De Klerk E, Lesaffre E, Van den Enden M. Improved compliance and persistence with atorvastatine through a pharmacybased intervention. Value Health 2003; 6: 635-809.
87. Zeger SL, Liang K-Y. Comment: dose-response estimands. J Am Stat Assoc 1991; 86: 18-19.
88. Delmas PD, Vrijens B, Roux C, Le-Moigne-Amrani A, Eastell R, Grauer A et al. Osteoporosis treatment using reinforcement with bone turnover marker data reduces fracture risk: the IMPACT study. Abstracts of the 2004 Annual Meeting of the American Society of Bone Metabolism Research, Miami Beach, FL, November 2004.
89. Harter JG, Peck CC. Chronobiology: suggestions for integrating it into drug development. Ann N Y Acad Sci 1991: 618: 563-71.
90. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22: 238-46.
91. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002; 17: 812-13.
92. Harrigan PR, Dong WY, Alexander C et al. The association between drug resistance and adherence determined by two independent methods in a large cohort of drug naïve individuals starting triple therapy. Abstract of the 2nd IAS Conference on HIV Treatment, Paris, France, July 2003.
93. Comté L, Reners C, Tousset E, Vrijens B. Once-daily versus twice-daily regimens: which is best for HIV infected patients? Abstracts of the Belgian Statistical Society annual meeting, Vielsalm, Belgium, Oct 8-9, 2004.
94. British National Formulary 44. British Medical Association: London, 2002; p. 261.
95. Meier P. Discussion. J Am Stat Assoc 1991; 86: 19-22.
96. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038-41.
97. Urquhart J. Patient compliance as an explanatory variable in four selected cardiovascular studies. In: Cramer JA, Spilker B, eds, Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991; pp. 301-22.
98. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 199; 86: 7-17.
99. Joyce CRB. Patient co-operation and the sensitivity of clinical trials. J Chron Dis 1962; 15: 1025-36.
100. Lasagna L, ed. Patient Compliance. Mount Kisco, NY: Futura, 1976.
101. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979.
102. Rubin D. Comment: dose-response estimands. J Am Stat Assoc 1991; 86: 22-4.
103. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-91.
104. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information-an application to the multiple risk factor intervention trial. Control Clin Trials 1993; 14: 79-97.
105. Goetghebeur E, Loeys T. Beyond intention to treat. Epidemiol Rev 2002; 24: 85-90.
106. Loeys T, Goetghebeur E. Causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance. Biometrics 2003; 59: 100-5.
107. Hill AB. (The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300. Available at: http://www.edwardtufte.com/tufte/hill/. Accessed: September 4, 2004.
108. Lasagna L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, eds, Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991; pp. 393-403.
109. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999; 15: 217-28.
110. Bachmann LHY, Stephens J, Richey CM, Hook EW. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26: 272-8.
111. PRILOSEC® (omeprazole) delayed-release capsules. Physicians' Desk Reference, 58th edn. Montvale, NJ: Thomson PDR, 2004; pp. 633-8.
112. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189-97.
113. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron R, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332: 918-22.
114. Weintraub M. Intelligent noncompliance and capricious compliance. In: Lasagna L, ed., Patient Compliance. Mount Kisco, NY: Futura, 1976; pp. 39-47.